National Cancer Registry

National Cancer Registry (NCR)

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 3mg	3mg	Capsule, prolonged release	68,645,618 L.L
S01EA05	ALPHAGAN P	B	Brimonidine tartrate - 1.5mg/ml	0.15%	Drops solution	999,819 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 1mg	1mg	Capsule, prolonged release	25,729,044 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 5mg	5mg	Capsule, prolonged release	85,485,667 L.L
L04AD02	ADVAGRAF	B	Tacrolimus monohydrate - 0.5mg	0.5mg	Capsule, prolonged release	13,297,758 L.L
B01AC06	ASPIRIN PROTECT	B	Acetylsalicylic acid - 100mg	100mg	Tablet, enteric coated	146,479 L.L
N06DA02	ARICEPT	B	Donepezil HCl - 10mg	10mg	Tablet, film coated	3,776,197 L.L
S01EA05	ALPHAGAN P	B	Brimonidine tartrate - 0.1%	0.15%	Drops solution	999,819 L.L
B01AC17	AGGRASTAT	B	Tirofiban hydrochloride monohydrate - 0.25mg/ml	0.25mg/ml	Injectable concentrated solution	18,280,324 L.L
S01EC04	AZOPT	B	Brinzolamide - 10mg/ml	10mg/ml	Drops suspension	804,962 L.L
A04AA05	ALOXI	B	Palonosetron HCl - 0.25mg/5ml	0.25mg/5ml	Injectable solution	3,656,595 L.L
A04AA55	AKYNZEO	B	Palonosetron - 0.5mg, Netupitant - 300mg		Capsule, hard	7,364,372 L.L
D06BB10	ALDARA	B	Imiquimod - 5%	5%	Cream	6,301,277 L.L
M04AA03	ADENURIC	B	Febuxostat - 120mg	120mg	Tablet, film coated	2,184,704 L.L
J06BA02	ARAGAM	BioHuman	Human normal immunoglobulin - 5g/100ml	5g/100ml	Injectable solution	40,075,575 L.L
B05AA01	ALBUKEY	BioHuman	Albumin human - 20%	20%	Injectable solution	4,863,366 L.L
B05AA01	ALBUREL HUMAN ALBUMIN BP	BioHuman	Albumin human - 20%	20%	Injectable solution	3,240,004 L.L
B05AA01	ALBUREL HUMAN ALBUMIN BP	BioHuman	Albumin human - 20%	20%	Injectable solution	6,353,687 L.L
B05AA01	ALBUTEIN	BioHuman	Albumin human - 20%	20%	Injectable solution	7,154,928 L.L
B05AA01	ALBUTEIN	BioHuman	Albumin human - 20%		Injectable solution	4,031,528 L.L
B05AA01	ALBUREL HUMAN ALBUMIN BP	BioHuman	Albumin human - 20%	20%	Injectable solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 80mg/4ml	80mg/4ml	Injectable concentrated solution	L.L
N02CD01	AIMOVIG	BioTech	Erenumab - 70mg/ml	70mg/ml	Injectable solution	35,423,371 L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 162mg/0.9ml	162mg/0.9ml	Injectable solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 200mg/10ml	200mg/10ml	Injectable concentrated solution	L.L
L04AC07	ACTEMRA	BioTech	Tocilizumab - 400mg/20ml	400mg/20ml	Injectable concentrated solution	L.L
B02BD08	ARYOSEVEN RT	BioTech	Eptacog alfa - 1mg	1mg	Injectable powder for solution+diluent	16,902,713 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB01	ACTRAPID	BioTech	Insulin (human) - 100IU/ml	100IU/ml	Injectable solution	752,552 L.L
A10AB06	APIDRA SOLOSTAR	BioTech	Insulin glulisine - 100IU/ml	100IU/ml	Injectable solution	3,942,834 L.L

...